|
2CRH
Solution structure of the SH2 domain of human proto-oncogene protein VAV1
Deposited 2005-05-20
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
629–775(147 aa)
Fragment:SH2 (residues 1-138)
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 7;298 K;Ionic strength (raw mmCIF value) 120 mM;Pressure ambient
NMR sample composition
1.15mM 13C,15N-labeled protein; 20mM d-Tris-HCl(pH7.0); 100mM NaCl; 1mM d-DTT; 0.02% NaN3 | 90% H2O/10% D2O
|
Resolution not provided
|
|
2LCT
Solution structure of the Vav1 SH2 domain complexed with a Syk-derived doubly phosphorylated peptide
Deposited 2011-05-09
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
664–767(104 aa)
Fragment:SH2 domain residues 664-767
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 7;298 K;Ionic strength (raw mmCIF value) 120;Pressure ambient
NMR sample composition
1.1 mM [U-13C; U-15N] protein, 20 mM TRIS, 100 mM sodium chloride, 1 mM DTT, 0.02 % sodium azide, 1.1 mM peptide, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided
|
|
2MC1
Solution structure of the Vav1 SH2 domain complexed with a Syk-derived singly phosphorylated peptide
Deposited 2013-08-13
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
664–767(104 aa)
Fragment:SH2 domain (UNP residues 664-767)
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 7;298 K;Ionic strength (raw mmCIF value) 120;Pressure ambient
NMR sample composition
1 mM [U-99% 13C; U-99% 15N] protein, 1 mM peptide, 20 mM TRIS, 100 mM sodium chloride, 1 mM DTT, 0.02 % sodium azide, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided
|
|
2ROR
Solution structure of the VAV1 SH2 domain complexed with a tyrosine-phosphorylated peptide from SLP76
Deposited 2008-04-08
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
629–775(147 aa)
Fragment:SH2 domain, UNP residues 629-775
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 7;296 K;Ionic strength (raw mmCIF value) 120;Pressure ambient
NMR sample composition
1.08mM [U-13C; U-15N] Proto-oncogene vav; 1.08mM tyrosine-phosphorylated peptide; 20mM [U-2H] TRIS; 100mM sodium chloride; 0.02% sodium azide; 1mM [U-2H] DTT; 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided
|
|
3BJI
Structural Basis of Promiscuous Guanine Nucleotide Exchange by the T-Cell Essential Vav1
Deposited 2007-12-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
189–565(377 aa)
Fragment:Vav1 DH/PH/CRD
|
Not recorded
|
ZN ZINC ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;298 K;17% PEG-3350, 100 mM HEPES, pH 7.5, 200 mM ammonium chloride, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.60 Å
R-free 0.293
|
|
3BJI
Structural Basis of Promiscuous Guanine Nucleotide Exchange by the T-Cell Essential Vav1
Deposited 2007-12-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
189–565(377 aa)
Fragment:Vav1 DH/PH/CRD
|
Not recorded
|
ZN ZINC ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;298 K;17% PEG-3350, 100 mM HEPES, pH 7.5, 200 mM ammonium chloride, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.60 Å
R-free 0.293
|
|
3KY9
Autoinhibited Vav1
Deposited 2009-12-04
|
Different construct
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
2–584(583 aa)
Fragment:CH-DH-PH-C1 DOMAINS
|
Not recorded
|
ZN ZINC ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;298 K;0.02 M TRIS, 0.05 M NACL, 5% GLYCEROL, 2 mM TCEP, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.73 Å
R-free 0.271
|
|
3KY9
Autoinhibited Vav1
Deposited 2009-12-04
|
Different construct
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
2–584(583 aa)
Fragment:CH-DH-PH-C1 DOMAINS
|
Not recorded
|
ZN ZINC ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;298 K;0.02 M TRIS, 0.05 M NACL, 5% GLYCEROL, 2 mM TCEP, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.73 Å
R-free 0.271
|
|
6NEW
Apo structure of the activated truncation of Vav1
Deposited 2018-12-18
|
Different construct
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
170–575(406 aa)
|
Not recorded
|
ZN ZINC ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.3;294 K;16-22% (v/v) Ethylene Glycol, 0.1M TRIS pH 7.3, and 15% (w/v) Polyethylene Glycol 8000
|
Resolution 2.50 Å
R-free 0.257
|
|
6NFA
Vav1 inhibited by an allosteric inhibitor: Vav1 inhibitors block GEF activity
Deposited 2018-12-19
|
Different construct
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
170–575(406 aa)
Fragment:UNP residues 170-575
|
Not recorded
|
ZN ZINC ION × 2
9K1 (2S)-2-{[3-(4-methylphenyl)imidazo[1,2-a]pyrazin-8-yl]amino}-3-(pyridin-3-yl)propan-1-ol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.3;294 K;16-22% v/v ethylene glycol, 0.1 M Tris, pH 7.3, 15% w/v PEG8000
|
Resolution 2.70 Å
R-free 0.242
|
|
9NFR
Crystal structure of CRBN-DDB1 and MRT-23227 in complex with VAV1
Deposited 2025-02-21
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain C
782–839(58 aa)
|
Not recorded
|
ZN ZINC ION × 1
A1BYX (3R)-3-{2-chloro-4'-[(1-methyl-1H-pyrazol-3-yl)methoxy][1,1'-biphenyl]-3-yl}piperidine-2,6-dione × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;2.6 % PEG Smear Low, 6.1 % PEG Smear Medium, 4.3 % PEG Smear High, 5 % glycerol, 0.1 M CaCl2, and 0.1 M MES pH 5.8
|
Resolution 3.40 Å
R-free 0.271
|